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Summary 
Cytotoxic T cells (CTL) recognize short peptide epitopes presented by class I glycoproteins encoded 
by the major histocompatibility complex (MHC). It is not yet known whether peptides containing 
posttranslationally  modified amino acids can also be recognized by CTL. To address this issue, 
we have studied the immunogenicity and recognition of a glycopeptide carrying an O-linked 
N-acetylglucosamine (GlcNAc) monosaccharide-substituted  serine residue. This posttranslational 
modification is catalyzed by a recently described cytosolic glycosyltransferase. We show that 
glycosylation does not affect peptide binding to MHC class I and that glycopeptides can elicit 
a strong CTL response that is glycopeptide specific. Furthermore, glycopeptide recognition by 
cytotoxic T  cells is dependent on the chemical structure of the glycan as well as its position 
within the peptide. 
T  lymphocytes recognize peptide antigens as  they are 
presented on the cell surface by polymorphic proteins 
encoded in the MHC class I or II. Class I MHC presents 
peptide fragments ofintracelhlar synthesized protein, whereas 
class II MHC predominantly presents peptide fragments of 
extracellular proteins  that have been degraded in the endo- 
cytic compartment (1). The allelic  specificity  of peptide binding 
to MHC is governed by pockets in the MHC binding groove 
that confer the preferred binding of certain amino acid residues 
within an allele-specific motif (2). 
All natural T cell antigens identified to date consist of pep- 
tides with unmodified amino acid side chains. However, it 
is not known whether some of the posttranslational modifica- 
tions that occur on proteins in vivo contribute to the recog- 
nition of peptide antigens by T cells. Thus, it is not known 
whether sulfated, phosphorylated,  carboxylated, or glycosyl- 
ated peptides can be selected for presentation by MHC with 
the posttranslational  modification intact. 
Studies on the recognition by CTLs ofpeptides haptenated 
with  trinitrophenyl  have  demonstrated that  T  cells will 
specifically recognize chemically modified peptide antigens 
(3). It is therefore possible that peptides carrying natural post- 
translational modifications, such as glycosylation, might simi- 
larly be recognized by T  cells. 
Several different types of protein glycosylation are known 
including  the  N-linked  glycosylation  of  asparagine  and 
O-linked glycosylation of serine and threonine occurring in 
the endoplasmic reticulum (ER) and Golgi apparatus. In ad- 
dition, a novel O-linked glycosylation, occurring almost ex- 
clusively on nuclear and cytosolic proteins, has been described 
(4).  This glycosylation  is characterized  by substitution of 
serines or threonines with single O-3-1inked N-acetylglucos- 
amine (GlcNAc) residues catalyzed by a cytosolic N-acetyl- 
glucosaminyl  transferase (reviewed in reference 5). 
Since peptide fragments of cytosolic and nuclear proteins 
are the preferred substrates for antigen presentation by class I 
MHC, it is possible that glycopeptides  derived from O-GlcNAc 
substituted cytosolic proteins could enter the class I presen- 
tation pathway.  When bound to MHC class I, the O-8- 
GlcNAc modification  on peptides could then be presented 
in such a way as to be specifically  recognized by T cell receptors. 
Here we report for the first time the efficient binding to 
class I MHC (H-2K  b and H-2D  b) of a synthetic glycopep- 
tide carrying this naturally occurring O-linked GlcNAc and 
its carbohydrate-specific recognition by CTL. 
Materials and Methods 
Reagents and Antibodies.  Fluorenylmethoxycarbonyl (Fmoc) 
amino acids and resins for the synthesis of peptides were purchased 
from Zinsser (Maidenhead, UK) and Novabiochem  AG (Notting- 
ham, UK). IMDM was from GIBCO, Ltd. (Glasgow, Scotland) 
and FCS from Seralab (Crawley Down, UK). 
The cell line RMA-S is a Rauscher virus-transformed murine 
T cell line that has a defective  TAP 2 gene encoding the peptide 
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second, human TAP-defective  cell line T2 (7), transfected with 
H2-K  b and  H2-D b,  was  maintained  as  described previously. 
C57BL/6 mice were obtained from Harlan Olac, Ltd. (Bicester, 
UK). Antibodies were purified from culture supernatant by affinity 
chromatography on protein-A Sepharose (Sigma Chemical Co., 
Poole, UK). The mAb Y3 recognizes a conformational epitope on 
the eel and ce2 domains of K  b (8) and mAb B22.249 recognizes a 
conformational epitope on the (xl domain of D b (9). 
Peptide Synthesis.  The Sendai virus nucleoprotein324-332 wild- 
type (wt) Peptide ([FAPGNYPAL]; amino acids are referred to by 
the single letter code) and the analogue K3 [FAPSNYPAL] were 
synthesized  manually  on Wang resin  using conventional  Fmoc  chem- 
istry. The solid phase synthesis, purification, and characterization 
of  the glycopeptides  IO-O-GIcNA~ [FAPS (O-B-GlcNAc) NYPAL], 
K3-O-N-acetyl-D-galactosamine  (GalNAc) [FAPS (O-c~-GalNAc) 
NYPAL], and K1-N-GIcNAc [FAPGN (N-~-GlcNAc) YSAL] will 
be reported elsewhere (Arsequell, G., A. C. Lellouch, S. Y. Wong, 
J. S. Hanrum, T. EUiott, and R. A. Dwek, manuscript in prepara- 
tion). Briefly,  three glycosyl  amino acids  were synthesized  as building 
blocks for solid-phase  glycopeptide  synthesis.  FmocSer (13-pGlcNAc) 
OH was  prepared by glycosylation of FmocSerOH with per- 
acetylated (p)GlcNAc using boron  trifluoride etherate catalysis. 
Glycosylation of Fmoc Serine pentafluorophenyl ester  (Fmoc- 
SerOpfp) with c~-pGalN3Br (obtained from n-Galactal [10]) using 
silver triflate as a catalyst afforded FmocSer (c~-pGalN3) Opfp. A 
coupling reaction between Fmoc aspartic t-butyl ester (FmocAspO 
tBu) and the glycosylamine of GlcNAc, followed by acetylation 
with acetic  anhydride  and cleavage  of  the tBu ester with TFA yielded 
FmocAsn (3-pGlcNAc) OH. The building blocks were purified 
and characterized  before incorporation  into the solid  phase glycopep- 
tide synthesis  by a standard Fmoc protocol using FmocLeu  deriva- 
tized  Wang  resin with  benzotriazole-l-yl-oxy-tri-pyrrolidino- 
phosphonium hexa  fluoroacetic  acid (PyBOP) as an activating  agent 
(except with the Opfp derivative which needed no further activa- 
tion). In the case of FmocSer (o~-pGalN3) Opfp, thioacetic acid 
was used to convert the azido group to the N-acetyl group while 
the glycopeptide  was still  resin  bound (11). The Peptides  were cleaved 
from the resin using TFA/HzO, purified by reverse phase HPLC 
to greater than 99%  purity,  and deacetylated using a catalytic 
amount of sodium methoxide in absolute methanol, followed by 
repurification  by HPLC. The peptides were characterized  by proton 
nuclear magnetic resonance, amino acid analysis,  hexosamine  anal- 
),sis (in the case of glycopeptides), and laser desorption mass spec- 
trometry. Amino acid and hexose contents were as expected, as 
were the parent ions of each compound. Sterile filtered stock solu- 
tions of Peptides (1-4 rag/m1 in PBS) were stored at  -70~ 
Assembly Assays.for Peptide Binding to MHC.  Assembly  assays 
for binding  of the  synthetic peptides to K  b and D b molecules 
metabolically  labded with [3SS]methionine  were carried out essen- 
tially as described  previously  (12). This assay  is based on the Peptide- 
dependent stabilization of K  b and D  b after lysis of the peptide 
transporter (TAP 2)-deficient cell line RMA-S and the detection 
by immunoprecipitation with the conformation-specific  antibodies 
Y3 and B22, respectively. Peptide binding was quantified by den- 
sitometry of the heavy chain band of autoradiographs after SDS- 
PAGE. Optical density was plotted against peptide concentration. 
Establishment 0fCTL.  C57BL/6 mice were immunized ingui- 
nally with 100/zg s.c. of Peptides K3 or K3-O-GlcNAc in incom- 
plete Freunds adjuvant. Antipeptide CTL were stimulated in vitro 
on day 7 as described  by Stauss et al. (13). RMA-S cells were cul- 
tured overnight  at 25~  to induce  high surface  expression  of(empty) 
K  b and D  b molecules (14) before pulsing for 2-4 h with 30/~M 
of the relevant peptide at 25~  and subsequent irradiation (7,000 
rad). After washing, 2  x  106 Peptide-pulsed RMA-S cells were 
used to stimulate 8  x  10  ~ spleen cells from immunized animals 
per well in 24-well  plates in basic medium (IMDM containing 10% 
FCS, with addition of penicillin, streptomycin, glutamine, and 
5 x  10 -s M 2-mercaptoethanol), and Peptides were added to the 
cultures (final  concentration 30/~M). After 7 d, cells were restimu- 
lated with 2 x  106 irradiated C57BL/6 spleen cells/well  and 5 #M 
peptide at a stimulator/responder ratio of 3:1 in complete medium 
(basic medium with 10% Con A supernatant). Thereafter,  the CTL 
lines were restimulated weekly as above. 
Cloning of T Cells.  CTL lines against K3 and K3-O-GlcNAc 
were cloned in 96-well plates by limiting dilution on irradiated pep- 
tide pulsed syngeneic spleen cells (2.5  x  10S/well) and tempera- 
ture-induced Peptide pulsed RMA-S cells (10s/well) in 100 ~1 com- 
plete medium. Another 100/A complete medium were added to 
each well on day 4 and good growing clones were transferred onto 
fresh feeder cells in 48-well plates on days 10-14. 
CTL Assays.  The peptide transporter-deficient cell line T2 
transfected with D b or K  b (T2-D  b or T2-K  b, respectively) were 
used as target cells conventional CTL assays. 
Results and Discussion 
The peptides used in this investigation (Fig.  1) were ana- 
logues of the CTL epitope FAPGNYPAL from Sendai virus 
nucleoprotein (15). This sequence was chosen because it con- 
tains  both  a  D b  (xxxxNxxxL)  and  a  K b  (xxxxxYxxL) 
binding motif (16, 17), allowing us to induce T cell responses 
to a single peptide presented by two different restriction ele- 
ments. Also, a crystal structure of the peptide FAPGNYPAL 
in complex with K b is available (18), enabling us to choose 
positions for carbohydrate modifications most likely to point 
out of the groove and interact with the TCR. 
The  wt  peptide  as  well  as  the  analogue  K3  and  its 
O-glycosylated counterpart K3-O-GIcNAc were synthesized 
and tested for their ability to bind K b and DL Fig. 2 shows 
that K3-O-GlcNAc bound to both K b and D b as efficiently 
as the wt peptide, when tested in the class I MHC RMA-S 
assembly assay, with half maximal binding at peptide con- 
centrations of 60 nM for K b and 12 nM for D b compared 
with 90 and 12 nM for wt, respectively. Similarly, the non- 
glycosylated K3 bound well to both K b and D b with half 
maximal binding at peptide concentrations of 160 and 22 
nM, respectively. It is interesting to note, that in a previous 
study, N-glycosylation of a class II-binding peptide (19) led 
to greatly reduced binding, regardless of the position of the 
modification  within the MHC binding region of the peptide. 
Having confirmed the efficient binding to K b and D b, K3 
and K3-O-GlcNAc were used to generate CTL. After 2 in 
vitro stimulations, the peptide specificity and MHC restric- 
tion of CTL lines were tested in standard SlCr release assays 
using peptide pulsed T2-K  b and T2-D  b as target cells. In ad- 
dition, lines were cloned by limiting dilution in order to ana- 
lyze the bulk response  of each line at the clonal level. We 
derived nine CTL clones specific for K3 and 5 for K3-O- 
GIcNAc. 
Immunization and restimulation with K3-O-GIcNAc gave 
rise to a CTL line with a high degree of specificity for the 
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Figure  1.  Peptide structure. The peptides used in this study were based 
on  a  Kb-restricted  CTL  peptide  epitope  (wt)  from  Sendai  virus 
nucleoprotein. K3- O-GIcNAc carries O-~-linked GlcNAc (R.I) at posi- 
tion 4 of K3.  K3-O-GalNAc has O-oMinked GalNAc (Rz) at position 
4. K1-N-GIcNAc carries N-13-1inked  GlcNAc (R~) at position 5 of wt as 
well as a P to S substitution at position 7, thus mimicking the natural 
N-glycosylation  sequon. 
glycosylated peptide with only marginal crossreactivity to- 
ward the nonglycosylated K3.  Both K b- and Db-restricted 
responses were generated (Fig. 3).  Analysis of CTL dones 
derived from this line showed that this was not due to cross- 
reactivity between the restriction elements, but instead to 
the presence of both K b- and Db-restricted dones specific for 
K3-O-GlcNAc  (Fig. 4, a  and b). All of the five clones de- 
rived from  CTL  lines induced with  K3-O-GlcNAc  were 
specific for the glycopeptide, regardless of restriction element. 
Similarly, immunization with the nonglycosylated coun- 
terpart K3 gave rise to lines specific for that peptide and with 
little crossreactivity with  the glycosylated K3-O-GIcNAc. 
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Figure 2.  Peptide and glycopeptide binding  to MHC. The binding of 
wt (hexagon),  K3 (box), and K3-O-GlcNAc (circle) to K b (a) and D b (b) 
was measured using an assembly assay as described previously (12). Pep- 
tide binding was quantified by densitometry of the class I MHC heavy 
chain band on autoradiographs  of SDS-PAGE gds. 
Again both K b- and Db-restricted responses were observed 
that did not appear to be the result of crossreactivity  when 
analyzed at the donal level (Fig. 3 b). All of the nine clones 
derived against K3 were thus restricted through K b (Fig.  4 
c). Only one done derived from immunization with K3 cross- 
reacted against  K3-O-GIcNAc  (data not shown). 
These results clearly demonstrate  the ability to generate 
specific class I MHC-restricted CTL responses to glycopep- 
tides, and suggest that the glycan moiety is involved in a specific 
contact  with TCR. 
To investigate this issue in more detail, we synthesized two 
analogues of K3-O-GlcNAc. The glycopeptide K3-O-GalNAc 
(Fig. 1) has an O-or-linked GalNAc at position 4 instead of 
the O-B-linked GlcNAc in K3-O-GlcNAc.  K3-O-GalNAc 
bound as well to both K b and D b as K3-O-GlcNAc  (half 
maximal binding at 50 and 11 riM, respectively).  This pep- 
tide was, however, not recognized by K3-O-GlcNAc-specific 
CTL lines (data not shown) or clones (Fig.  5), despite  the 
fact that K3-O-GlcNAc only differs from K3-O-GalNAc by 
the anomeric  glycosyl linkage to serine and the orientation 
of the hydroxyl group on C4 of the glycan ring (see Fig. 
1). This result lends strong support to the interpretation, that 
the K3-O-GlcNAc-specific  CTL recognition is partly  due 
to specific interaction between the TCR and the solvent ac- 
cessible surface area of the glycan moiety of K3-O-GlcNAc 
when complexed with K b or D b. 
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Figure 3.  Peptide specificity and MHC restriction of CTL lines. CTL 
lines from mice immunized  with K3-O-GlcNAc (a) or K3 (b) were tested 
in CTL assays using the cell lines T2-K  b (open) or T2-D  b (closed) as target 
cells prepuised with 10/~M of the peptides K3-O-GicNAc (c/g/e), K3 (box), 
or without peptide (triangle). 
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Peptide specificity and MHC restriction of CTL clones. T 
cell clones against peptides K3-O-GlcNAc  (a and b) or K3 (c) obtained 
by limiting dilution were tested in CTL assays against T2-Kb (open) or 
T2-D  b (closed) sensitized with 10 #M peptide K3-O-GIcNAc (circle), K3 
(box), or without peptide (triangle). The Kb-restricted clone K3G.9 (a) 
was also tested against K1-N-GlcNAc (diamond). 
We also synthesized the glycopeptide K1-N-GlcNAc, which 
carries an N-linked GlcNAc residue at position 5 (as well 
as a P to S substitution at position 7). K1-N-GIcNAc was 
also  shown to bind efficiently  to  K b with  half maximal 
binding at 200 nM but was not recognized by any of the 
CTL  lines  (data  not  shown),  nor by  Kb-restricted  CTL 
clones specific  for K3-O-GlcNAc (Fig. 4 a). This result demon- 
strates that the K3-O-GlcNAc-specific CTL response was sen- 
sitive to the position of the glycan in the modified peptide. 
The asparagine at position 5 (NS) of the wt peptide FAPG- 
NYPAL is considered an anchor residue required for efficient 
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Figure 5.  CTL clones recog- 
nize K3-O-GlcNAc but not K3- 
O-GalNAc.  The  CTL  clone 
K3G.4 was tested against T2-D  b 
target cells sensitized with K3-O- 
GlcN.Ax (clrc/e), K3-O-GalNAc 
(diamond), K3 (box),  or without 
peptide (triangle). 
binding of peptides to D b (17). Accordingly, we found that 
N-GlcNAc modification of N5 resulted in a dramatic decrease 
in the binding to D b (half maximal binding >10 #M) but 
not K  b (half maximal binding 200 riM). This peptide was 
also not recognized by any K3-O-GlcNAc-specific Db-re  - 
stricted clones  (data not shown). 
In a separate set of experiments, CTL lines raised against 
K1-N-GlcNAc  only  displayed  reactivity  towards  T2-K  b 
prepulsed with K1-N-GlcNAc,  but not when prepulsed with 
K3-O-GlcNAc, or a nonglycosylated analogue, or when using 
T2-D  b as targets (data  not shown). 
Other groups have raised MHC class II-restricted T cells 
to glycopeptides (19, 20).  These studies showed, however, 
that potent immunogenicity was only retained when pep- 
tides were glycosylated outside the MHC binding region of 
the peptide.  In one of these studies T  cells generated to 
glycopeptides of high immunogenicity  crossreacted with the 
nonglycosylated peptide (19); whereas in another study T 
cell hybridomas were generated that reacted preferentially with 
glycosylated peptide but at the same time showed equal reac- 
tivity towards dramatically different NH2-terminal glycosy- 
lations (20).  Furthermore, T  cells generated to the non- 
glycosylated peptide reacted equally well, or better, towards 
the NH~-terminally substituted glycopeptide. 
We have demonstrated that a dass I MHC binding pep- 
tide can be modified by O-glycosylation within the MHC 
binding region without affecting its binding to MHC dass 
I. The resulting peptides are highly immunogenic, and elicit 
carbohydrate-slx-cific, MHC-restricted,  antiglycopeptide CTL. 
Furthermore, the O-fl-linked GlcNAc substitution used in 
the present study is the first example of T cell recognition 
of a naturally occurring type of glycosylation. Proteins car- 
rying this glycosylation which have been identified to date 
include RNA polymerase transcription factors, cytoskeletal 
proteins, nuclear pore proteins, neurofilaments, and oncogene 
products (5). Also, cytosolic proteins from Leishmania (21) 
and viral proteins (22, 23) have  been shown to carry O-linked 
GlcNAc. 
The fact that O-GlcNAc monosubstituted serine and threo- 
nine residues are frequently found in cytosolic and nuclear 
proteins means that peptides derived from the cytosolic degra- 
dation of these proteins could enter the MHC class I presen- 
tation pathway (1). Recognition of glycosylated peptides (and 
other posttranslational modifications) could therefore be of 
significant importance in immunity towards malignant dis- 
eases and in viral infections.  In addition, it is possible that 
the acquisition or loss of glycosylation might provide a novel 
strategy for viruses or malignantly transformed cells to es- 
cape from selection pressure by CTL (24,  25), which does 
not depend on a mutation at the gene level. Furthermore, 
the loss  or  acquisition of oligosaccharide  residues  in en- 
dogenously presented peptides could lead to the formation 
of neoantigens, loss of tolerance, and development of autoim- 
munity. 
The relevance of studying T cell responses to posttransla- 
tional modifications such as glycosylation now depends on 
the identification of a naturally occurring epitope of this kind. 
This potentially new group of peptide epitope determinants 
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T cell epitope mapping conventionally has been achieved using 
synthetic peptides. The isolation of glycopeptides complexed 
with MHC class I molecules would be another approach to 
identifying this kind of epitope. The fact that no glycopep- 
tides have so far been detected amongst the pool of peptides 
eluted from MHC class I could simply reflect the technical 
difficulties encountered in detecting OoGIcNAc modifications 
by Edman degradation and mass spectroscopy,  even when they 
are specifically looked for (26). Indeed, using techniques  specific 
for the detection of carbohydrate modifications, we have ob- 
tained preliminary data supporting the presence of O-GlcNAc 
modified peptides amongst the pool ofpeptides eluted from 
human spleen class I MHC (Haurum, J.S., unpublished ob- 
servations). 
Furthermore,  glycopeptides might only comprise a small 
fraction of the peptides presented by MHC. This would not 
detract from their potential significance, since the relative abun- 
dance of individual peptides presented on the cell surface does 
not correlate with their importance as T  cell antigens.  Sev- 
eral  immunodominant  antigens  have thus  been extremely 
difficult to isolate from antigen-presenting  cells in amounts 
sufficient for sequence analysis  (27). 
The subcelluhr location of the cytosolic glycosylation with 
O-linked GlcNAc could yield glycopeptides that are capable 
of entering the MHC class I presentation pathway. Our study 
shows that O-GIcNAc substitution is a promising candidate 
for a naturally occurring type of glycosylation capable of being 
recognized by CTL in an MHC-restricted  way. 
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